Ensuring that patients remain consistent with their therapies is one of the major challenges facing healthcare, so what if you could make treatment a game?
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh